Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study
Open Access
- 1 January 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Research in Medical Sciences
- Vol. 24 (1) , 30
Abstract
Background: Breast cancer is the most common diagnosed female cancer. Breast cancer is also the leading cause of cancer death in females accounting for 13.7% of female cancer-related mortality globally. Variable known prognostic factors such as histological tumor type, tumor size, nodal status, grade, age, and estrogen receptor (ER) status and the proliferation marker – Ki-67 influence the type of treatment decision. The purpose of this present study is to investigate the association between Ki-67 expression with several clinicopathological variables and patients’ outcome. Materials and Methods: This is a retrospective cohort study from September 2008 to March 2017; 165 newly diagnosed breast cancer patients were enrolled in the study. Ki67 levels were measured using immunohistochemistry and compared with clinicopathological variables. The relation of Ki67 expression with disease-free survival (DFS) and overall survival (OS) was also analyzed. Results: The result of this study revealed that age, tumor size, menopausal status, and human epidermal growth factor receptor 2 (HER2) status had no effect on the patients’ outcome. Patients with ER-positive, progesterone receptor (PR)-positive, and HER2-negative tumors expressed a higher rate of Ki-67 (>10%) than patients with ER-negative, PR-negative, and HER2-positive tumors, respectively. However, we found that Ki-67 levels were not significantly increased statistically with ER, PR, and HER2 statuses. There was a statistically significant correlation between Ki-67 expression and with higher stages of the disease. Multivariate analysis showed that Ki-67 expression could not to be an independent prognostic factor for 5-year OS and DFS. Furthermore, p53 status was only prognostic factor for 5-year OS whereas higher stages of disease and p53 status were prognostic factors for 5-year DFS. Conclusion: Ki67 could not be an independent variable for prediction of breast cancer outcome.Keywords
This publication has 26 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryBreast Cancer Research and Treatment, 2013
- Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancersBreast Cancer, 2013
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Prognostic and Predictive Factors in Early-Stage Breast CancerThe Oncologist, 2004
- Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinomaCancer, 2003
- The important prognostic value of Ki-67 expression as determined by image analysis in breast cancerJournal of Cancer Research and Clinical Oncology, 1996
- Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinomaBreast Cancer Research and Treatment, 1996
- Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytesCytometry, 1991